No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval cytarabine / daunorubicin liposomal formulation Sensitive : A1
U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C2 – Inclusion Criteria cytarabine / daunorubicin liposomal formulation Resistant : C2	cytarabine/daunorubicin liposomal formulation Resistant: C2 – Inclusion Criteria cytarabine / daunorubicin liposomal formulation Resistant : C2
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C2 – Inclusion Criteria cytarabine / daunorubicin liposomal formulation Resistant : C2	cytarabine/daunorubicin liposomal formulation Resistant: C2 – Inclusion Criteria cytarabine / daunorubicin liposomal formulation Resistant : C2
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
CBL mutation	Acute Myelogenous Leukemia	CBL mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
CEBPA mutation	Acute Myelogenous Leukemia	CEBPA mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
PHF6 mutation	Acute Myelogenous Leukemia	PHF6 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
STAG2 mutation	Acute Myelogenous Leukemia	STAG2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
FLT3 A848P + MLL-MLLT3 fusion	Acute Myelogenous Leukemia	FLT3 A848P + MLL-MLLT3 fusion	Acute Myelogenous Leukemia	ARO-002 + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials ARO-002 + cytarabine / daunorubicin liposomal formulation Sensitive : C3	ARO-002 + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials ARO-002 + cytarabine / daunorubicin liposomal formulation Sensitive : C3
Chr rearrangement(11)(q23)	Acute Myelogenous Leukemia	Chr rearrangement(11)(q23)	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials midostaurin + cytarabine / daunorubicin liposomal formulation Sensitive : C3	midostaurin + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials midostaurin + cytarabine / daunorubicin liposomal formulation Sensitive : C3
KDM6A mutation	Acute Myelogenous Leukemia	KDM6A mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Sensitive : C4	cytarabine/daunorubicin liposomal formulation Sensitive: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Sensitive : C4

DNA polymerase inhibitor

DNA polymerase inhibitor

Associations(19)

Associations
(19)